Delving into the Latest Updates on GL Pharm Tech Corp. with Synapse

The Purpose of This Clinical Study is to Prove That the Test Drug (AJU-S56 5%) is Superior to the Control Drug After 24 Weeks of Administration to Patients Who Have Moderate or Severe Dry Eye Syndrome

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.

开始日期2023-11-10

申办/合作机构

Aju Pharm Co. Ltd.

[+1]

NCT06337981 / Completed临床2期

A Phase 2 Multicenter, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AJU-S56 in Patients With Dry Eye Disease

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56) compared to control drug(vehicle) in Patients with Dry Eye Disease.

开始日期2021-11-22

申办/合作机构

Aju Pharm Co. Ltd.

[+1]

NCT04679883 / Unknown status临床2期

A Phase 2 Multicenter, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease

This study is a randomized, double-blind, placebo-controlled phase 2 clinical trial to evaluate the efficacy and safety of GLH8NDE in patients with Dry Eye Disease.

开始日期2021-04-01

申办/合作机构

GL Pharm Tech Corp.

100 项与 GL Pharm Tech Corp. 相关的临床结果

登录后查看更多信息

0 项与 GL Pharm Tech Corp. 相关的专利（医药）

登录后查看更多信息

10

项与 GL Pharm Tech Corp. 相关的文献（医药）

2021-07-01·International Journal of Biological Macromolecules1区 · 化学

Montelukast microsuspension with hypromellose for improved stability and oral absorption

1区 · 化学

Article

作者: Park, Dong Woo ; Kim, Dong Yoon ; Choi, Yong Seok ; Park, Jun Sang ; Kim, Eun Jeong ; Park, Hyun Jin ; Lee, Ha Ryeong ; Song, Woo Heon ; Kang, Myung Joo ; Ho, Myoung Jin ; Park, Jun Soo ; Lee, Hyo Chun

Oral montelukast (MTK) is prescribed to treat asthma or rhinitis, and is clinically investigated as new medication in the treatment of Alzheimer's dementia. Herein, in order to better patient's compliance, microsuspensions (MSs)-based oral liquid preparations of montelukast (MTK) were formulated with polymeric suspending agents including hypromellose (HPMC), and those drug-polymer interaction, physicochemical stability, dissolution, and in vivo pharmacokinetic profile was evaluated. When amorphous MTK particle was suspended in aqueous vehicle, it was readily converted into crystalline form and grown into aggregates, drastically lowering dissolution rate. However, the addition of HPMC polymer markedly suppressed the crystal growth, providing both improved drug stability and profound dissolution profile. Raman spectrometry denoted the inter-molecular hydrogen boding between MTK particle and HPMC polymer. The crystal growth or dissolution profile of MSs was markedly affected by pharmaceutical additives (sucrose or simethicone) in the preparations or storage temperature. The optimized HPMC-based MS exhibited over 80% higher bioavailability, compared to marketed granule (Singulair®) in rats. Therefore, novel MTK-loaded MS can be a promising liquid preparation, bettering oral absorption and patient's compliance.

2019-12-01·Laboratory Animal Research

Metabolomics approach to serum biomarker for laxative effects of red Liriope platyphylla in loperamide-induced constipation of SD rats

Article

作者: Bae, Su Ji ; Hwang, Dae Youn ; Choi, Yusang ; Lee, Young Ju ; Kang, Hyun Gu ; Ryu, Sung Ha ; Kim, Suhkmann ; Choi, Hyeon Jun ; Park, Ji Won ; Lim, Yong ; Kim, Kyu-Bong ; Kang, Mi Ju ; Kim, Ji Eun

Red Liriope platyphylla (RLP) is a known herbal medicine used in the treatment of some chronic diseases including constipation, neurodegenerative disorders, diabetes and obesity. To determine and characterize putative biomarkers that predict the laxative effects induced by RLP treatment, alteration of endogenous metabolites was measured in the serum of loperamide (Lop)-induced constipation rats after administration of RLP extract (EtRLP) using ¹H nuclear magnetic resonance (¹H NMR) spectral data. The urine volume and amounts, and weights and water contents of stools were significantly recovered in the Lop + EtRLP treated group as compared to the No group, whereas body weight and food intake maintained constant levels. Also, significant recoveries in the thickness of mucosa and muscle were detected in the colon of the Lop + EtRLP treated group. Furthermore, pattern recognition showed absolutely different clustering of the serum analysis parameters when comparing the Lop treated group and Lop + EtRLP treated group. Of the 33 endogenous metabolites, 7 amino acids (alanine, arginine, glutamate, glutamine, glycine, threonine and valine) and 8 endogenous metabolites (betaine, creatine, glucose, taurine, ethanol, lactate, glycerol and succinate) were dramatically increased in the Lop + EtRLP treated SD rats. These results provide the first evidence pertaining to metabolic changes in the constipation rats treated with Lop + EtRLP. Additionally, these findings correlate with changes observed in 15 metabolites during the laxative effects of EtRLP.

2019-01-01·The Journal of Toxicological Sciences

<sup>1</sup>H NMR toxicometabolomics following cisplatin-induced nephrotoxicity in male rats

Article

作者: Lee, Jung Dae ; Kim, Kyu-Bong ; Kim, Siwon ; Kim, Suhkmann ; Kim, Ji Won ; Ryu, Sung Ha

Cisplatin (CP) is an anti-cancer drug used for treatment of solid tumors, but the major adverse effect is drug-induced nephrotoxicity. The current study aimed to determine biomarkers that might predict nephrotoxicity induced by CP using serum or urinary proton nuclear magnetic resonance (¹H NMR) spectral data in male Sprague-Dawley (S-D) rats. CP (0, 0.5 or 5 mg/kg) was intraperitoneally (i.p.) administered for single dose. Animals were sacrificed 2 days (D2) or 8 days (D8) after administration of CP in order to perform analysis of serum biochemistries and histopathologic examination. Urine samples were collected every 24 hr from pre-treatment to sacrifice. Serum and urinary ¹H NMR spectral data revealed apparent differential clustering between control and CP-treated groups as evidenced by principal component analysis (PCA) and orthogonal projections to latent structures-discriminant analysis (OPLS-DA) in global and targeted profiling. The concentrations of endogenous serum metabolites, alanine, betaine, glucose, glutamine, lactate, and leucine were significantly increased on D2. Urinary concentrations of alanine, glucose, glycine, guanidinoacetate, acetate, and lactate were significantly elevated on D2 or D8, whereas concentrations of urinary metabolites, citrate and hippurate were significantly decreased on D2 or D8. The correlation of serum and urinary ¹H NMR OPLS-DA with serum biochemistry and renal histopathologic changes suggests that ¹H NMR urinalysis may be used to reliably predict or screen CP-induced nephrotoxicity. Data suggest that these altered endogenous metabolites might serve as specific biomarkers for CP-induced nephrotoxicity.

100 项与 GL Pharm Tech Corp. 相关的药物交易

登录后查看更多信息

100 项与 GL Pharm Tech Corp. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

6

2

临床1期

临床3期

2

3

申请上市

其他

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

普瑞巴林 ( CACNA2D1 x CACNA2D2 )	神经痛更多	申请上市
GLK2DS	糖尿病更多	申请上市
GLH1SM	糖尿病更多	申请上市
非那雄胺/坦洛新 ( 5α-reductase x α1A-AR )	前列腺增生症更多	临床3期
Recoflavone ( LT )	干眼综合征更多	临床3期